Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-MGMT morpholino oligonucleotides
- Development stage
- Preclinical
- Lead developer
- Oregon Health & Science University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Anti-MGMT morpholino oligonucleotides (AMONs) are a class of antisense oligonucleotide research compounds designed to silence the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT). MGMT is a primary mechanism of resistance to alkylating chemotherapies, such as temozolomide, in glioblastoma and other solid tumors. AMONs utilize a neutral phosphorodiamidate morpholino backbone, which provides high stability and target affinity compared to traditional ribose-based oligonucleotides. By binding to MGMT mRNA, they block translation, reducing MGMT protein levels and sensitizing tumor cells to chemotherapy. Research at Oregon Health & Science University (OHSU) has also explored using sub-lethal ionizing radiation to enhance the intracellular uptake of these oligonucleotides in tumor cells.
- Other names
- anti-MGMT morpholinosMGMT morpholino oligonucleotides
02
Targets
MGMT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on anti-MGMT morpholino oligonucleotides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-MGMT morpholino oligonucleotides.